In part A, ORR was 0% in the monotherapy group vs. 7% in the combination group; in immune refractory NSCLC, no difference in ORR was reported (3% in both groups), while in NSCLC naïve group assigned only to the combination arm ORR was 26% in combination group regardless of PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.